Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Cologuard is easy for patients to use and easy for doctors to interpret the results, said Dr. Casey Allen, a surgical oncologist at Allegheny Health Network in Pennsylvania.

On Tuesday, Stifel reaffirmed its Buy rating and $67.00 price target for Exact Sciences (NASDAQ: EXAS), following the announcement of a Medicare reimbursement increase for the company's Cologuard ...

The 2024 PGA TOUR Champions season continues after a week off following the Trophy Hassan II in Morocco, where Argentina's Ricardo Gonzalez pulled away on the b ...

With March serving as National Colorectal Cancer Awareness Month, there’s no better way to play a role than by simply to help raise awareness. That’s the missio ...